Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hendrik Jähnig is active.

Publication


Featured researches published by Hendrik Jähnig.


American Journal of Clinical Pathology | 2008

Methylene Blue-Assisted Lymph Node Dissection in Colon Specimens A Prospective, Randomized Study

Bruno Märkl; Therese Gannon Kerwel; Hendrik Jähnig; Daniel Oruzio; Hans Arnholdt; Claus Schöler; M. Anthuber; Hanno Spatz

Recently, we introduced ex vivo intra-arterial methylene blue injection into the inferior mesenteric artery as a novel method to improve lymph node (LN) harvest in rectal cancer. We have now adapted this method to the other segments of the colon. A total of 60 cases were enrolled. Primary LN dissection was followed by fat clearance and a secondary dissection. The mean +/- SD primary LN harvest differed highly significantly with 35 +/- 18 and 17 +/- 10 LNs in the methylene blue-stained and unstained groups, respectively. Primary insufficient LN harvest occurred in 8 cases of the unstained group and in only 1 case of the methylene blue-stained group (P = .0226). After secondary dissection, upstaging was seen exclusively in the unstained group. The time/LN ratio differed significantly with 0.9 and 0.6 min/LN in the unstained and methylene blue-stained groups, respectively. Intraarterial methylene blue injection is recommended as a routine technique in the histopathologic study of colon cancer.


Modern Pathology | 2012

The clinical significance of lymph node size in colon cancer

Bruno Märkl; Janine Rößle; Hans Arnholdt; Tina Schaller; Ines Krammer; Claudio Cacchi; Hendrik Jähnig; Gerhard Schenkirsch; Hanno Spatz; Matthias Anthuber

To date, the clinical value of lymph node size in colon cancer has been investigated only in a few studies. Only in radiological diagnosis is lymph node size routinely recognized, and nodes ≥10 mm in diameter are considered pathologic. However, the few studies regarding this topic suggest that lymph node size is not a reliable indicator of metastatic disease. Moreover, we hypothesized that increasing lymph node size is associated with favorable outcome. By performing a morphometric study, we investigated the clinical significance of lymph node size in colon cancer in terms of metastatic disease and prognosis. A cohort of 237 cases with excellent lymph node harvest (mean lymph node count: 33±17) was used. The size distribution in node-positive and -negative cases was almost identical. In all, 151 out of the 305 metastases detected (49.5%) were found in lymph nodes with diameters ≤5 mm. Only 25% of lymph nodes >10 mm showed metastases. Minute lymph nodes ≤1 mm were involved only very rarely (2 of 81 cases). In 67% of the cases, the largest positive lymph node was <10 mm. The prognostic relevance of lymph node size was investigated in a subset of 115 stage I/II cases. The occurrence of ≥7 lymph nodes that were >5 mm in diameter was significantly associated with better overall survival. Our data show that lymph node size is not a suitable factor for preoperative lymph node staging. Minute lymph nodes have virtually no role in correct histopathological lymph node staging. Finally, large lymph nodes in stage I/II disease might indicate a favorable outcome.


Journal of Surgical Oncology | 2010

Tumour budding, uPA and PAI‐1 are associated with aggressive behaviour in colon cancer

Bruno Märkl; I. Renk; Daniel Oruzio; Hendrik Jähnig; Gerhard Schenkirsch; C. Schöler; W. Ehret; Hans Arnholdt; M. Anthuber; Hanno Spatz

The proteases PAI‐1 and uPA play a major role in extracellular matrix degradation, which facilitates tumour progression. Tumour budding is a histomorphological expression of enhanced tumour cell migration.


American Journal of Clinical Pathology | 2010

Shape Is Not Associated With the Origin of Pericolonic Tumor Deposits

Katharina Wünsch; Jenny Müller; Hendrik Jähnig; Robert A. Herrmann; Hans Arnholdt; Bruno Märkl

Pericolonic tumor deposits (PTDs) are associated with an adverse outcome in colorectal cancer. According to the International Union Against Cancer they are classified as N1 or V1/V2 depending on their shape. This recommendation, however, is not well supported by the literature. To elucidate the origin of PTDs, we performed a histomorphologic study of 69 PTDs, which were found in 7 of 21 colorectal specimens using the whole-mount step-section technique. Depending on the origin, the nodules were classified as venous invasions, lymphatic invasions, nerve sheath infiltrations, free PTDs, and continuous growth in 18 (26%), 3 (4%), 6 (9%), 34 (49%), and 8 (12%) of 69 PTDs, respectively. Polycyclic and oval-round shapes were identified in all categories. Continuous growth was found only within the inner third of the adhering fat, whereas the other morphologic features were found in all regions. The data of this study do not support PTD classification on the basis of their shape.


Human Pathology | 2010

Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer

Bruno Märkl; Hans Arnholdt; Hendrik Jähnig; Gerhard Schenkirsch; Robert A. Herrmann; Karlheinz Haude; Hanno Spatz; M. Anthuber; Günther Schlimok; Daniel Oruzio

Maspin has been characterized as a potent tumor suppressor in many in vitro and in vivo studies. In contrast, in stage III colon cancer, an association with shorter overall survival as well as sensitivity to chemotherapy was found for cases with nuclear maspin expression. Because 20% of node-negative colorectal cancer cases show a fatal clinical course, we hypothesized that immunohistochemical maspin expression could be of help to identify higher-risk cases. Therefore, we analyzed survival in a study employing 156 cases of stage I/II colorectal cases. Immunohistochemical cytoplasmic and/or nuclear maspin expression was found in 72% and 48% of the cases, respectively. Significant correlations between cytoplasmic expression and high tumor grade (P < .01) and between nuclear expression and tumor budding (P < .001) were shown. No differences concerning overall survival and immunohistochemical maspin expression were found when the complete collective was analyzed. However, evaluation of the pT3 cases revealed a highly significant worse mean overall survival of cases with a combination of nuclear expression and cytoplasmic loss of maspin compared to cases with the opposite expression pattern nuclear loss and cytoplasmic expression (mean overall survival 40 versus 63 months, respectively; P < .001). The other possible combinations (complete positive and complete negative) showed intermediate mean overall survival times with 54 and 49 months, respectively. Our findings suggest a compartment-dependent function of maspin in colorectal cancer, which can be useful in identifying stage II cases with a higher risk for fatal outcome with a possible benefit from adjuvant chemotherapy.


Annals of Surgical Oncology | 2010

A new concept for the role of ex vivo sentinel lymph nodes in node-negative colorectal cancer.

Bruno Märkl; Hans Arnholdt; Hendrik Jähnig; Hanno Spatz; M. Anthuber; Daniel Oruzio; Therese Gannon Kerwel


International Journal of Colorectal Disease | 2012

Clinical significance of lymph vessel density in T3 colorectal carcinoma.

Claudio Cacchi; Hans Arnholdt; Hendrik Jähnig; M. Anthuber; A. Probst; Daniel Oruzio; Bruno Märkl


Annals of Surgical Oncology | 2011

Combination of Ex Vivo Sentinel Lymph Node Mapping and Methylene Blue-Assisted Lymph Node Dissection in Gastric Cancer: A Prospective and Randomized Study

Bruno Märkl; Alexandra I. Moldovan; Hendrik Jähnig; Claudio Cacchi; Hanno Spatz; M. Anthuber; Daniel Oruzio; Hallie Kretsinger; Hans Arnholdt


Pathologe | 2008

Lymph node preparation in colorectal cancer. Ex vivo methylene blue injection as a novel technique to improve lymph node visualization

Bruno Märkl; Therese Gannon Kerwel; Hendrik Jähnig; M. Anthuber; Hans Arnholdt


Pathologe | 2007

Lymphknotenpräparation bei kolorektalen Karzinomen

Bruno Märkl; Therese Gannon Kerwel; Hendrik Jähnig; M. Anthuber; Hans Arnholdt

Collaboration


Dive into the Hendrik Jähnig's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Claudio Cacchi

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge